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Aryloxymaleimides for cysteine modification,
disulfide bridging and the dual functionalization
of disulfide bonds†
Cristina Marculescu,a Hanno Kossen,a Rachel E. Morgan,a Patrick Mayer,a
Sally A. Fletcher,a Berend Tolner,b Kerry A. Chester,b Lyn H. Jonesc and
James R. Baker*a
Tuning the properties of maleimide reagents holds significant promise in
expanding the toolbox of available methods for bioconjugation. Herein
we describe aryloxymaleimides which represent ‘next generation
maleimides’ of attenuated reactivity, and demonstrate their ability
to enable new methods for protein modification at disulfide bonds.
The maleimide motif 1 is a highly reactive conjugate acceptor and
can be employed eﬀectively in selective reactions with thiols, such as
cysteine residues in proteins.1 As a result it is one of the most widely
used functional groups in bioconjugation (Scheme 1). We have
recently described bromomaleimides 3 as the parent members of
a new class of reagents, which can be termed ‘next generation
maleimides’ (NGMs). The incorporation of the leaving group leads to
a switch in the mechanism that occurs upon reaction with a thiol,
from an addition reaction to an addition–elimination reaction.
The result is the formation of a thiomaleimide product 4, rather
than thiosuccinimide 2. Such next generation maleimide reagents
enable new applications including reversible cysteine modification,2
the construction of triconjugates,2b,3 and the bridging of disulfide
bonds.2b,4
We envisaged that the choice of leaving group on the maleimide
core could result in reagents with finely tuned properties. For
example the reactivity could be controlled, in a manner similar
to the use of iodo-, bromo- and chloroacetamides as varyingly
reactive reagents for selective cysteine modification.5 In addition
to guiding the reactivity, the choice of leaving group could
also control other properties of the reagents, such as aqueous
solubility. Herein we report on the aryloxymaleimides, as NGMs
of attenuated reactivity, and demonstrate application of these
reagents in cysteinemodification and in newmodes of conjugation
of disulfide bonds.
Having previously shown that thiophenol served as a suitable
leaving group in dithiophenolmaleimide reagents,4b we postulated
that phenol may do like-wise. Furthermore we considered that
the increased mesomeric contribution from the oxygen into the
maleimide ring would lead to reagents of reduced electrophilicity.
The synthesis of aryloxymaleimides 6–8 was carried out by simple
addition of the corresponding phenol toN-methyl bromomaleimide 5
(Scheme 2).
Addition of these reagents to a model protein, the single
cysteine mutant (L111C) of the SH2 domain of the Grb2 adaptor
protein 9,2b was monitored over 2 hours and compared to the
use of bromomaleimide 5 (Fig. 1). All three aryloxymaleimides
underwent the desired addition–elimination reaction to afford
thiomaleimide conjugate 10, at a reduced rate compared to
bromomaleimide 5.2b As expected, the incorporation of electronScheme 1 Cysteine labelling of proteins using maleimide 1 and next
generation maleimide (NGM) 3.
Scheme 2 Synthesis of monoaryloxymaleimides 6–8.
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withdrawing groups on the aryloxy ring (7 and 8) led to an accelera-
tion in rate compared to the unsubstituted phenoxymaleimide 6. It is
notable that the aryloxymaleimides are still considerably more
reactive than iodoacetamide, another commonly employed cysteine
reactive reagent, which underwent o5% reaction with this protein
after 30 min under the same conditions.2b Furthermore the reaction
could be accelerated by increasing the number of equivalents of
phenoxymaleimide 6 to ten, leading to complete conversion to
the product in just 10 min. These results demonstrate that
phenoxymaleimides represent cysteine modification reagents
of attenuated reactivity, a feature we postulated could be useful
in affording improved selectivity in certain bioconjugations.
A particular regioselectivity problem had become apparent in our
studies on disulfide bridging for which we envisaged that the
aryloxymaleimides could oﬀer an ideal solution. We were interested
in attempting to use bromomaleimide to bridge a disulfide bond in
the peptide hormone somatostatin 11, in a manner related to our
work with dibromomaleimide.2b,4b This would aﬀord a saturated
dithiosuccinimide 14 (presumed to be as a mixture of diastereo-
mers), in contrast to the dithiomaleimides generated by dibromo-
maleimide bridging. Such dithiosuccinimides would be expected to
have diﬀerent properties to dithiomaleimides (e.g. reduced reactivity
with thiols)2b,3b and could serve as a complementary approach.
However, addition of bromomaleimide 5 to reduced somatostatin
12 led to a mixture of the desired bridged adduct 14 and the bis-
addition product 15 (Scheme 3). Thus addition of bromomaleimide to
the second thiol in intermediate 13 was competing with the bridging
reaction. What was required was an NGM analogue which
underwent a slower reaction with cysteine, to ensure that the
cyclisation of 13 would take place before the second maleimide
addition. The aryloxymaleimides appeared to fit this specifica-
tion. Indeed treatment of reduced somatostatin 12with phenoxy-
maleimide 6 led after 1 h to quantitative conversion to the
succinimide bridged somatostatin conjugate 14. Increasing the
amount of phenoxymaleimide to 10 equiv. in this reaction still
aﬀorded none of the bis-labelled product 15, demonstrating the
extremely high selectivity for disulfide bridging. To prove that
succinimide bridging had reached completion, product 14 was
treated with 1 equiv. ofmaleimide. No reaction was observed by LC-
MS analysis after 5 min at room temperature, proving the absence
of detectable amounts of free thiol.
We also found that, unlike bromomaleimides,4b aryloxym-
aleimides are resistant to cross-reactivity with the reducing agent
TCEP and therefore that the succinimide bridging could be
carried out in situ. The optimised in situ conditions involve
addition of 1.5 equiv. aryloxymaleimide to the peptide followed
by addition of the equimolar amount of the reducing agent TCEP
leading to quantitative conversion after 2 h. In situ protocols are
valuable in disulfide bridging as they limit the amount of time
the peptide or protein lacks its bridging functionality and thus
reduces the propensity to aggregate or unfold.4b,6
A selection of derivatised aryloxymaleimides (Fig. 2) were then
synthesised (see ESI,† Scheme S1) to explore the scope of this
succinimide bridging. Notably a new, scalable synthesis of bromom-
aleimidewas developed to allow convenient access to thesemolecules.
A water soluble aryloxy motif was incorporated in 16 to investigate the
possibility of organic solvent free labelling. A ‘miniPEG’ phenoxym-
aleimide 17was developed as amodel for PEGylation of proteins, and
rhodamine phenoxymaleimide 18 for fluorescent labelling.
The use of the water soluble aryloxymaleimide 16 successfully
enabled the labelling of somatostatin under organic solvent free
conditions. It is noteworthy that this is the first example of a
maleimide reagent incorporating a water solubilising group which
is released upon conjugation, and further exemplifies the enhanced
versatility of NGMs over traditional maleimides.
To demonstrate that the succinimide bridging was also applicable
to larger proteins, chemical modification of an antibody fragment
Fig. 1 Addition of aryloxymaleimides to Grb2 SH2 (L111C), with a graph of
conversion over time measured by LCMS.
Scheme 3 Succinimide bridging of the disulfide bond in somatostatin.
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was investigated. A substantial portion of all biotechnology products
under development are antibodies or antibody fragments,7 and
homogeneous conjugation technologies have a key role to play in
realising the full potential in this area.6,8 Treatment of cystine
stabilized anti-carcinoembryonic antigen single chain Fv fragment
(anti-CEA ds-scFv) 196 with N-miniPEG phenoxymaleimide 17 and
benzeneselenol as the reducing agent6 led to quantitative conversion
to the conjugate 20 (Scheme 4). The same outcomewas observe using
N-methyl phenoxymaleimide 6 to aﬀord conjugate 21.
We have previously demonstrated that maleimide bridges are
susceptible to thiol mediated cleavage at high concentration of
thiols, such as the mM concentrations found in the cytoplasm of
cells.2b,6 We wanted to test the stability of the succinimide bridge
to thiols, to investigate if a diﬀerent reactivity profile was
demonstrated. Treatment of succinimide bridged scFv conjugate
21 with 100 equiv. GSH (7 mM, pH 7.4) led to no reaction even
after 48 h at room temperature. Thus the succinimide bridge in
this scFv is completely resistant to thiol mediated cleavage in
contrast to the maleimide bridge.
Returning to somatostatin however, it became apparent that
this thiol stability is variable depending on the exact nature of the
disulfide bridge. A comparison of maleimide and succinimide
bridged somatostatin revealed that both were cleaved at similar
rates by GSH under cytoplasmmimicking conditions to release the
free peptide 12 (see ESI,† Fig. S1). We propose that the mechanism
for the thiol cleavage of the succinimide bridge starts with a retro-
conjugate addition to generate acyclic thiomaleimide 13 (see
Scheme 3), and thus 13 and 14 are in fact in equilibrium.
Thiomaleimide 13 is then cleaved by GSH in a manner consistent
with our previous results,9 via a conjugate addition–elimination
sequence. The difference in thiol stability of the somatostatin–
succinimide 14 to the scFv-succinimide 20 we postulate to be
attributable to the extent of intramolecular interactions that are
present constraining these structures. In the case of somatostatin
the formation of acyclic thiomaleimide intermediate 13 can be
followed by a shift in conformation reducing the rate of rebridging
and allowing a significant amount of this intermediate to form in
solution. In contrast in the case of the scFv the extensive inter-
actions between the variable regions of the light and heavy chain
hold the cysteines in close proximity, precluding the formation of
significant amounts the acyclic thiomaleimide intermediate
required for thiol mediated cleavage.
Notably employing N-phenyl phenoxymaleimide to bridge
somatostatin led to the resultant conjugate which underwent
rapid hydrolysis of the succinimide bridge (consistent with the
equivalent N-phenyl maleimide bridge,4a and see ESI,† Fig. S2),
aﬀording a succinamic acid which was completely stable to
thiols; this represents a general method of producing completely
thiol stable conjugates.
Whilst the focus of this study was investigating the use of
phenoxymaleimides in succinimide bridging, we realised that the
reversibility of the bridging oﬀered an interesting possibility for dual
labelling of disulfide bonds. We envisaged that addition of a second
electrophile could lead to interception of intermediate 13, attaching a
second tag. Dual labelling of a reduced disulfide bond is extremely
diﬃcult to achieve using traditional reagents as it relies on a
significant diﬀerence in reactivity between the two cysteines.10
Methods for the site-selective dual-labelling of peptides are widely
sought, to allow controlled introduction of multiple functionalities.11
For example, the incorporation of two diﬀerent fluorophores allows
FRET studies while the attachment of an in vivo stabilising group (e.g.
a PEG) and a drug can prospectively enable therapeutic applications.
Thus treatment of reduced somatostatin 12withphenoxymaleimide
6 (R1 = Me) aﬀorded the succinimide bridged somatostatin 14 which
was then treated, without purification, with monobromomaleimide
Fig. 2 Aryloxymaleimide derivatives.
Scheme 4 Succinimide bridging of ds-scFv shMFE.
Scheme 5 Dual modification of somatostatin (conditions: 1. 1 h, r.t.,
pH 6.4; 2. 2 h, 37 1C, pH 6.4).
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(R2 = H) (Scheme 5). The reaction required warming to 37 1C for 2 h to
ensure complete conversion to the dual modified peptide 22. To
confirm the formation of two cleavable thiomaleimides the conjugate
was treated with 2-mercaptoethanol (100 equiv.) to quantitatively
convert to reduced somatostatin. To demonstrate that this approach
could be employed to access dual functionalised peptides, we con-
structed miniPEG–fluorescein and rhodamine–fluorescein bis-
conjugates (23 and 24). Notably other electrophiles can also be
employed in the second modification step; for example maleimide
was employed affording a dual conjugate in which one of the tags was
cleavable by thiols and the other was not. Trypsin digest of 25
confirmed that the reaction led, as expected, to a mixture of the two
possible regioisomers (see ESI,† Fig. S3).
In conclusion, by varying the leaving groups on a maleimide core,
a range of next generationmaleimides can be producedwith tuneable
properties. Here a selection of aryloxymaleimides have been demon-
strated to serve as eﬃcient cysteine labelling reagents of attenuated
reactivity. This enables the aryloxymaleimides to be employed in
succinimide bridging, oﬀering a novel strategy for disulfide labelling.
The reversibility of the succinimide bridge in the peptide also enabled
a one-pot dual labelling strategy to be developed.
The authors gratefully acknowledge Pfizer, BBSRC and UCL
for supporting this work.
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